vatalanib has been researched along with isoniazid in 1 studies
Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
---|---|---|---|---|---|
276 | 42 | 98 | 21,815 | 960 | 4,493 |
Protein | Taxonomy | vatalanib (IC50) | isoniazid (IC50) |
---|---|---|---|
Myeloperoxidase | Homo sapiens (human) | 4.85 | |
Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for vatalanib and isoniazid
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |